Cortex sends complete CX717 response to FDA

By Lisa Kerner

Charlotte, N.C., Sept. 11 - Cortex Pharmaceuticals, Inc. sent its complete response to the Food and Drug Administration addressing toxicology issues surrounding its ampakine compound, CX717.

Ampakine compounds are believed to play a part in memory and behavior problems in Alzheimer's disease and other psychiatric diseases.

The FDA has 30 days to respond, by either removing or maintaining its clinical hold, according to a company news release.

The Irvine, Calif.-based neuroscience company said it has kept to its original testing timeline and is confident in its response to the FDA.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.